Immunotherapy-related adverse events (irAEs) were reported in 23 (24.7%) patients in the PD-1 inhibitor group and 33 (32.7%) patients in the PD-L1 inhibitor group, including 5 (5.4%) and 5 (5.0%) patients with grade 3–4 irAEs, such as pneumonitis and liver/pancreatic toxicity, respectively. Here, CD274 is linked to pneumonitis.